Can't find any questions here

Tigecycline

Cefepime/taniborbactam is only drug used for MBL variant Klebsella Pneumonia and if Esbl variant Klebsella pneumonia, then use Avibactum drug preferably.

Where is the question?

What questions????

What is the question

caz-avibactam plus aztreonam and cefiderocol

Multidisciplinary approach with monitoring of different factors

Please, what's the question here?

Multi disciplinary approach, monitoring patients spO2, antibiotics ceftazidime-avibactam plus aztreonam and cefiderocol,measuring lactate level, fluid resuscitation, measure urine output. Vasopressor support might be needed. HrCT to rule out fungal infection. Proper hand hygiene and PPE for staff.

ceftazidime-avibactam with aztreonam can be used as antimicrobial

Dose adjustment need to be done based on renal parameters

Supportive treatment for other conditions Strict infection control protocol should be followed considering the standard precaution and droplet precaution. As patient is in intubation aerosolo generating procedure need to be protected by aerosol precaution.

Considering NDM K. pneumoniae, along with multiple comorbidities including CKD, Colisitn is not right option. However, Ceftazidime-avibactam and Aztreonam combination would be the justified for this patient.

I'll provide a structured approach to addressing this complex case.

*Patient Profile:*

- 70-year-old patient with multiple comorbidities:

- Atrial fibrillation

- Diabetes mellitus

- Chronic renal disease

- History of severe COVID-19 pneumonia (requiring mechanical ventilation and tracheostomy)

*Presenting Symptoms:*

- Recurrent infections

- Fever

- Hypotension

- Identification of Klebsiella pneumoniae producing New Delhi metallo-beta-lactamase (NDM)

*Key Considerations:*

1. Immunocompromised state due to age, comorbidities, and history of severe COVID-19

2. Increased risk of multidrug-resistant (MDR) infections

3. Presence of NDM-producing Klebsiella pneumoniae, indicating potential antibiotic resistance

4. Severity of symptoms (fever, hypotension) suggesting sepsis or severe infection

*Questions to Address:*

1. What are the appropriate empirical antibiotic regimens for this patient, considering the NDM-producing pathogen?

2. What diagnostic tests should be performed to identify the source and extent of the infection?

3. What are the management strategies for sepsis and hypotension in this patient?

4. How should the patient's underlying comorbidities be managed concurrently?

5. What are the implications for infection control and prevention in this case?

6. What are the potential outcomes and prognosis for this patient?

7. Are there any specific considerations for antimicrobial stewardship in this scenario?

*Pre-Session Preparation:*

Before joining the MedAll Infectious Diseases forum discussion, consider reviewing:

1. Guidelines for managing MDR infections (e.g., IDSA, ESCMID)

2. Antibiotic susceptibility patterns for NDM-producing Klebsiella pneumoniae

3. Sepsis management protocols (e.g., Surviving Sepsis Campaign)

4. COVID-19-related complications and immune system impacts

5. Relevant literature on managing complex infections in immunocompromised patient

1. Clinical Presentation: Key Features Suggesting MBL-Producing Infection

>The patient’s recurrent infections, fever, hypotension, and identification of Klebsiella pneumoniae producing New Delhi Metallo-beta-lactamase (NDM) indicate a severe, drug-resistant infection. The history of prolonged hospital stays and invasive procedures further supports this diagnosis.

2. Clinical Presentation: Differences from Typical Klebsiella pneumoniae Infection

>MBL-producing Klebsiella pneumoniae causes infections that are more difficult to treat due to resistance to most beta-lactam antibiotics, including carbapenems. Symptoms may persist or worsen despite initial broad-spectrum antibiotic therapy, unlike typical cases that often respond well to standard treatments.

3.Risk Factors: Predisposing Factors for MBL-Producing Infection

>the patient’s multiple comorbidities (e.g., diabetes, chronic renal disease), history of severe COVID-19 requiring mechanical ventilation, tracheostomy, and prolonged hospital exposure increase the risk of colonization and infection with multidrug-resistant organisms like MBL-producing Klebsiella pneumoniae.

4. Diagnostic Approach: Confirming MBL-Producing Organisms

>Diagnostic tests should include culture and sensitivity testing, molecular assays (e.g., PCR) to detect the NDM gene, and phenotypic tests like the Modified Hodge Test or Carbapenem Inactivation Method to confirm carbapenemase production. These canbe a guide targeted therapy.

5.Therapeutic Considerations: Challenges in Treatment

> Treating MBL-producing organisms is challenging due to limited antibiotic options. Combination therapies (e.g., ceftazidime-avibactam with aztreonam) or newer agents like cefiderocol may be necessary. Adjusting therapy for renal function and avoiding further resistance are critical challenges.

6.Infection Prevention and Control: Measures to Prevent Spread

>Implement strict infection control protocols, including isolation of the patient, hand hygiene practices, use of personal protective equipment (PPE), and environmental cleaning. Regular screening of high-risk patients and antimicrobial stewardship programs are essential to minimize the spread of MBL-producing org.

To manage the recurrent infections in the patient with NDM-producing Klebsiella pneumoniae:

1. **Antibiotic Therapy**: Use ceftazidime/avibactam plus aztreonam.

2. **Comorbidity Management**: Control atrial fibrillation, diabetes, and chronic renal disease.

3. **Infection Control**: Implement strict hospital infection control measures.

4. **Monitoring**: Regularly monitor and adjust treatment as needed.

Tigecycline or Colistin, with close monitoring, IV fluids and labs.

Managing this case may require a multidisciplinary approach: colistin or tigecycline can be given for klebsiella , as NDM is highly resistant pathogen. But before that renal function should be measured. Glycemic control strictly monitoring. RFT, Blood culture, CBC, Pro-calcitonin, Echo, ABG should be monitored

In managing a 70-year-old patient with a complex medical history and recurrent infections due to Klebsiella pneumoniae producing (NDM), the strategy should focus on:

Infection Control and Management by antibiotic therapy initiate targeted antibiotic therapy based on sensitivity patterns. Since NDM-producing organisms are resistant to many beta-lactam antibiotics, consider using:

Carbapenems(if susceptible)

Polymyxins (e.g., colistin or polymyxin B)

Aminoglycosides (e.g., amikacin)

Newer agents like ceftazidime-avibactam or meropenem-vaborbactam, if available and appropriate.

Source Control: Identify and manage potential sources of infection (e.g., abscesses, infected devices).

For managing the preexisting symptoms other the NDM's one supportive care should be in focus like

Fluid Resuscitation: Address hypotension with IV fluids, considering the patient's renal function.

Vasopressors: If the patient remains hypotensive despite adequate fluid resuscitation, consider initiating vasopressors (e.g., norepinephrine) to maintain perfusion.

Monitoring and Adjustments after observing the results of given antibiotics:

Close Monitoring: Regularly monitor vital signs, renal function, and laboratory parameters to assess response to treatment.

Adjust Therapy: Be prepared to adjust antibiotic therapy based on clinical response and susceptibility results.

1. NDM Klebsiella pneumoniae: A carbapenem-resistant bacterium producing New Delhi Metallo-β-lactamase.

2. Source: Tracheostomy site, urinary catheter, or hospital-acquired colonization.

3. Concerns: Infection control, sepsis management, comorbidity optimization.

4. Antibiotics: Colistin, tigecycline, fosfomycin, or cefiderocol (based on sensitivity).

5. Supportive Care: Fluids, vasopressors, renal monitoring, and ventilatory support.

As history highlights many complications and diseases at one time with geriatric patient

So maybe we should prefer board spectrum antibiotics for him

Or use same lab tests to identify the actual bacterium

I think at this age where immunity is too low we can go with antibacterial agents and shouldn’t use antibiotics .. new technology like drugs conjugate with NP and beneficial bacteria which can reduces that effects ..

Tigecycline

previous i Prolonged ventilation and low immunity status because DM ESRD affect the patient’s health

he is on septic shock needs septic screening and icu management